Billerica, Massachusetts, August 28, 2017 — MilliporeSigma today announced that it has entered into an agreement to acquire Natrix Separations, an Ontario, Canada-based provider of hydrogel membrane products for single-use chromatography. The transaction is expected to close in Q3 of 2017. Financial details were not disclosed.
Natrix is known for its unique technology platform capable of delivering high productivity and impurity removal in a single-use format, an ideal fit with next generation processing. This acquisition complements MilliporeSigma’s efforts to drive next-generation bioprocessing, ultimately enabling faster, more efficient technology for customers.
“The Natrix technology platform, and the development options and capabilities that this brings for single-use and rapid cycling chromatography, will allow us to accelerate our offering in mAb and vaccine manufacturing,” said Udit Batra, CEO, MilliporeSigma. “This acquisition creates tremendous opportunity to drive growth and advancement in next-generation processing—an area of increasing importance to our customers.”
Next-generation processing is any technology, expendable or system that changes the existing monoclonal antibody manufacturing template through unit operation intensification, connection of unit operations or fully continuous processing. Biomanufacturers are moving toward next-generation processing because of its many benefits, including increased plant productivity, facility flexibility, cost efficiencies and reduced risk. Next-generation processing is expected to triple in market size between 2020 and 2025.
Natrix markets both an anion exchange membrane and cation exchange membrane. Natrix is developing additional products to enable a fully single-use, full-scale biological purification process.
“Joining MilliporeSigma gives us the opportunity to collaborate with some of the best minds in the industry, allowing us to further the great work done by our scientists,” says John Chickosky, CEO, Natrix Separations. “I am truly excited to become part of a larger effort and see the benefits of this combination in the advances we will make for our customers and the global scientific community.”
About Natrix Separations, Inc.
Natrix Separations enables fast and flexible manufacturing of biopharmaceuticals through high-productivity disposable downstream processing products. The innovative Natrix HD Membranes overcome the limitations in efficiency, speed, and flexibility imposed by conventional capital-intensive approaches to chromatography. Natrix products feature well-established industry-standard chemistries, and are scalable from R&D to commercial manufacturing. Natrix is headquartered in Burlington, Ontario, Canada. For additional information, visit www.natrixseparations.com
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing, and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science, and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.